Leukemia research最新文献

The role of interim bone marrow assessments in acute myeloid leukemia – A systematic review and meta-analysis 中期骨髓评估在急性髓性白血病中的作用——一项系统回顾和荟萃分析。

IF 2.2 4区医学

Leukemia research Pub Date : 2025-10-12 DOI: 10.1016/j.leukres.2025.108121

Yuanli Lei , Zhiting Tang , Jessica A. Reese , Omer Jamy , Mohamad Khawandanah , Manu Pandey , Muhammad Faisal , Adam Asch , Zimu Gong

{"title":"The role of interim bone marrow assessments in acute myeloid leukemia – A systematic review and meta-analysis","authors":"Yuanli Lei , Zhiting Tang , Jessica A. Reese , Omer Jamy , Mohamad Khawandanah , Manu Pandey , Muhammad Faisal , Adam Asch , Zimu Gong","doi":"10.1016/j.leukres.2025.108121","DOIUrl":"10.1016/j.leukres.2025.108121","url":null,"abstract":"<div><h3>Background</h3><div>The current standard of care for acute myeloid leukemia (AML) patients undergoing intensive induction chemotherapy includes an interim bone marrow biopsy around day 14 (D14BM), and reinduction for patients with more than 5 % residual blasts on D14BM (Positive D14BM). However, this approach has become increasingly controversial. This systematic review and meta-analysis assess the sensitivity, specificity, and predictive value of D14BM in patients treated with one cycle of induction chemotherapy and evaluate the efficacy of reinduction versus observation in patients with Positive D14BM.</div></div><div><h3>Methods</h3><div>A systematic literature search was conducted using PubMed, Embase, Web of Science, and Cochrane databases. A bivariate model was used for pooled sensitivity and specificity. The positive predictive value was estimated based on pooled mean sensitivity, specificity, and historical refractory leukemia prevalence. Risk ratios (RR) for complete remission (CR) were meta-analyzed to compare reinduction versus observation in Positive D14BM patients.</div></div><div><h3>Result</h3><div>Among 1044 identified articles, 12 met inclusion criteria. Ten studies (1683 patients) evaluated the predictive value of D14BM, with a sensitivity of 49.7 % (proportion of refractory cases correctly identified by Positive D14BM) and specificity of 86.2 %. The estimated positive predictive value was 38.9 %, assuming a 15 % prevalence of true refractory leukemia. Eleven studies (832 patients) evaluated efficacy of reinduction, with a pooled RR of 1.00 (61 % vs. 60 %, 95 % CI: 0.76–1.31) for CR.</div></div><div><h3>Conclusion</h3><div>Positive D14BM has limited predictive power for refractory leukemia. Reinduction based on Positive D14BM does not improve CR rates compared to observation alone only and may expose patients to undue toxicity.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"159 ","pages":"Article 108121"},"PeriodicalIF":2.2,"publicationDate":"2025-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145318432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to "The SMAC mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and SMAC" [Leuk. Res., 36(2011) 784-90]. “SMAC模拟物RMT5265.2HCL通过抑制XIAP和促进线粒体细胞色素C和SMAC的释放诱导EBV和HTLV-I相关淋巴瘤细胞凋亡”[Leuk]的更正。Res., 36(2011) 784-90]。

IF 2.2 4区医学

Leukemia research Pub Date : 2025-10-10 DOI: 10.1016/j.leukres.2025.108115

Sampath Ramachandiran, Joan Cain, Albert Liao, Yanjuan He, Xiangxue Guo, Lawrence H Boise, Haian Fu, Lee Ratner, Hanna Jean Khoury, Leon Bernal-Mizrachi

引用次数: 0

Infectious complications in pediatric acute lymphoblastic leukemia treatment: A comparison of ALL-IC BFM 2009 vs. modified St. Jude total XV in a single-center retrospective cohort study 儿科急性淋巴细胞白血病治疗中的感染并发症：一项单中心回顾性队列研究中ALL-IC BFM 2009与改良St. Jude total XV的比较

IF 2.2 4区医学

Leukemia research Pub Date : 2025-10-08 DOI: 10.1016/j.leukres.2025.108120

Dilara Unal , Fatma Gumruk , Selin Aytac , Baris Kuskonmaz , Muhammed Dogukan Aksu , Fatma Visal Okur , Tekin Aksu , Mehmet Ceyhan , Ates Kara , Ali Bulent Cengiz , Yasemin Ozsurekci , Sule Unal

{"title":"Infectious complications in pediatric acute lymphoblastic leukemia treatment: A comparison of ALL-IC BFM 2009 vs. modified St. Jude total XV in a single-center retrospective cohort study","authors":"Dilara Unal , Fatma Gumruk , Selin Aytac , Baris Kuskonmaz , Muhammed Dogukan Aksu , Fatma Visal Okur , Tekin Aksu , Mehmet Ceyhan , Ates Kara , Ali Bulent Cengiz , Yasemin Ozsurekci , Sule Unal","doi":"10.1016/j.leukres.2025.108120","DOIUrl":"10.1016/j.leukres.2025.108120","url":null,"abstract":"<div><div>Infectious complications remain the major cause of treatment-related morbidity and mortality in pediatric patients with acute lymphoblastic leukemia (ALL). This study retrospectively compared the patterns of infection in children treated with either the modified St. Jude Total XV protocol (n = 181) or the ALL-IC BFM 2009 protocol (n = 61) at a single center. Although the overall number of infection episodes was similar between the two groups, their distributions across treatment phases differed markedly. The ALL-IC BFM 2009 protocol was associated with a significantly greater incidence of infections during the induction phase, particularly in high-risk patients, who often presented with skin and gastrointestinal tract infections. In contrast, modified St. Jude Total XV protocol presented a greater infection risk during the re-induction phase. Gram-positive bacteria, especially <em>Staphylococcus epidermidis</em>, were the most frequently isolated pathogens in both cohorts, although the BFM group exhibited a higher proportion of gram-negative infections. The rates of documented viral infections in BFM cohort and modified St. Jude Total XV cohort were 21.4 % vs 9.2 %, respectively. Invasive fungal infection rate was found as 6.7 % in the modified St. Jude group and 4.0 % in the BFM group is in line with the literature. Multivariate analysis confirmed that severe neutropenia and the presence of a central venous catheter were strong independent predictors of infection frequency. These findings underscore protocol-specific differences in infectious risk profiles and emphasize the importance of tailored supportive care strategies in the management of pediatric ALL.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"158 ","pages":"Article 108120"},"PeriodicalIF":2.2,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Applicability of current prognostication models for MDS patients with DDX41 mutation 当前DDX41突变MDS患者预后模型的适用性

IF 2.2 4区医学

Leukemia research Pub Date : 2025-10-06 DOI: 10.1016/j.leukres.2025.108118

Nadia Toumeh, Yazan Jabban, Rong He, David Viswanatha, Dragan Jevremovic, Patricia T. Greipp, James M. Foran, Talha Badar, Cecilia Y. Arana Yi, Yael Kusne, Antoine N. Saliba, Mehrdad Hefazi Thorghabeh, Aasiya Matin, William J. Hogan, Mithun V. Shah, Abhishek A. Mangaonkar, Mrinal M. Patnaik, Hassan B. Alkhateeb, Aref Al-Kali

引用次数: 0

Low serum complement C3 levels are associated with adverse clinical outcomes in myelodysplastic syndromes 低血清补体C3水平与骨髓增生异常综合征的不良临床结果相关

IF 2.2 4区医学

Leukemia research Pub Date : 2025-10-03 DOI: 10.1016/j.leukres.2025.108116

Duobing Zou , Huanhuan Ying , Liang Yong , Jie Cao , Yanqing Liu , Guifang Ouyang , Qitian Mu

{"title":"Low serum complement C3 levels are associated with adverse clinical outcomes in myelodysplastic syndromes","authors":"Duobing Zou , Huanhuan Ying , Liang Yong , Jie Cao , Yanqing Liu , Guifang Ouyang , Qitian Mu","doi":"10.1016/j.leukres.2025.108116","DOIUrl":"10.1016/j.leukres.2025.108116","url":null,"abstract":"<div><h3>Background</h3><div>Complement C3, a critical component of the complement system, has been implicated in cancer risk across various malignancies. However, its role in myelodysplastic syndromes (MDS) remains inadequately explored. This study investigates the impact of serum complement C3 levels on survival outcomes in patients with MDS.</div></div><div><h3>Methods</h3><div>Clinical data, including demographic characteristics (sex and age), hematological indices (white blood cell count and platelet count), bone marrow blast percentage, immunoglobulin levels (IgG, IgM, and IgA), and complement components (C3, C4, and Factor B), were retrospectively analyzed in 145 patients with MDS. Serum C3 levels were compared quantitatively between healthy controls and patients with MDS. Univariate and multivariate Cox proportional hazards regression analyses were employed to identify prognostic factors associated with clinical outcomes in MDS.</div></div><div><h3>Results</h3><div>A significant reduction in peripheral blood complement C3 levels was observed in patients with MDS compared to healthy controls (P < 0.0001). Patients with lower serum C3 levels exhibited notably poorer clinical outcomes, including reduced overall survival (OS; P = 0.019) and leukemia-free survival (LFS; P = 0.043). Multivariate Cox regression analysis, incorporating the Revised International Prognostic Scoring System (IPSS-R) but not the Molecular IPSS (IPSS-M), identified serum C3 levels below 79 mg/dL as an independent prognostic factor for both OS (P = 0.041) and LFS (P = 0.005).</div></div><div><h3>Conclusion</h3><div>Decreased serum complement C3 levels emerge as an independent prognostic biomarker in MDS, correlating with unfavorable clinical outcomes regardless of IPSS-R stratification. This novel parameter offers additional prognostic value and may enhance existing risk assessment tools in the clinical management of MDS.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"158 ","pages":"Article 108116"},"PeriodicalIF":2.2,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145268630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia 评估完全缓解/缓解率作为复发/难治性慢性淋巴细胞白血病的替代终点

IF 2.2 4区医学

Leukemia research Pub Date : 2025-09-27 DOI: 10.1016/j.leukres.2025.108113

Lin Wang , Murat Kurt , Tim Disher , Fei Fei Liu , Samantha Craigie , Serena K. Perna , Elise Aronitz , Toby A. Eyre , Loic Ysebaert , Matthew S. Davids

{"title":"Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia","authors":"Lin Wang , Murat Kurt , Tim Disher , Fei Fei Liu , Samantha Craigie , Serena K. Perna , Elise Aronitz , Toby A. Eyre , Loic Ysebaert , Matthew S. Davids","doi":"10.1016/j.leukres.2025.108113","DOIUrl":"10.1016/j.leukres.2025.108113","url":null,"abstract":"<div><div>Achieving complete response/remission (CR) by International Workshop on Chronic Lymphocytic Leukemia 2018 criteria indicates complete remission of leukemia in all disease compartments. We evaluated CR rate as a surrogate endpoint for progression-free survival (PFS) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) using data from randomized controlled trials (RCT). A systematic literature review was conducted to identify RCTs with ≥ 2 treatment arms, parallel group design, and reporting CR rate and PFS in patients with R/R CLL/SLL. Association between treatment effects on CR rate and corresponding PFS changes contrasting treatment and control arms was estimated using a weighted linear model, Daniels and Hughes model, and Riley bivariate random-effects meta-analysis. Association between absolute CR rate and PFS within individual treatment arms was estimated using nonparametric (Cox) and parametric (exponential, Weibull, Gompertz) proportional hazards models. Twenty RCTs were identified including 5765 patients with R/R CLL/SLL investigating various treatments (Bruton tyrosine kinase inhibitors, a B-cell lymphoma 2 inhibitor, phosphatidylinositol 3-kinase inhibitors, chimeric antigen receptor T-cell therapy, anti-CD20 monoclonal antibody, chemotherapy). Across RCTs, higher odds of CR resulted in statistically significant lower hazards of disease progression/death, where each 10 % increase in CR rate was associated with a 26 % (95 % confidence interval, 22 %<img>30 %) reduction in risk of progression/death. Cross-validation analyses demonstrated that treatment effects on CR rate reasonably predicted PFS benefits. Results were broadly consistent across different models. This study supports CR rate as an essential treatment goal and a valid surrogate endpoint in R/R CLL/SLL.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"158 ","pages":"Article 108113"},"PeriodicalIF":2.2,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to "CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy" [Leuk. Res., 85 (2019) 106198]. “CircPAN3通过调节自噬参与急性髓系白血病的耐药”的更正[Leuk]。Res., 85(2019) 106198]。

IF 2.2 4区医学

Leukemia research Pub Date : 2025-09-23 DOI: 10.1016/j.leukres.2025.108111

Jin Shang, Wei-Min Chen, Shan Liu, Zhi-Hong Wang, Tian-Nan Wei, Zhi-Zhong Chen, Wen-Bing Wu

引用次数: 0

Genes with altered expression by 5-Aza treatment in myeloid leukemia cells through methylation in intron 1 5-Aza处理通过内含子1甲基化改变髓系白血病细胞表达的基因

IF 2.2 4区医学

Leukemia research Pub Date : 2025-09-23 DOI: 10.1016/j.leukres.2025.108112

Machiko Fujioka , Hiroyuki Mishima , Hidehiro Itonaga , Yo Hamaguchi , Uladzislau Korzun , Koji Ando , Akira Kinoshita , Yasushi Miyazaki , Koh-ichiro Yoshiura

{"title":"Genes with altered expression by 5-Aza treatment in myeloid leukemia cells through methylation in intron 1","authors":"Machiko Fujioka , Hiroyuki Mishima , Hidehiro Itonaga , Yo Hamaguchi , Uladzislau Korzun , Koji Ando , Akira Kinoshita , Yasushi Miyazaki , Koh-ichiro Yoshiura","doi":"10.1016/j.leukres.2025.108112","DOIUrl":"10.1016/j.leukres.2025.108112","url":null,"abstract":"<div><div>5-Azacitidine (5-Aza) is a hypomethylating agent with demonstrated therapeutic efficacy for myeloid leukemia. The aim of this study was to identify the genes that mediate the cell killing effect of 5-Aza against leukemia cells through their expression changes and DNA demethylation. RNA sequencing revealed 54 genes with increased transcription levels in both SKM-1 and KG-1a myeloid leukemia cell lines treated with 5-Aza. Long read sequencing revealed 79 genes in which intron 1 exhibited significant DNA demethylation after 5-Aza treatment. Forty-three genes showed both increased gene expression and DNA demethylation in intron 1 in cells treated with 5-Aza. Enrichment signaling pathway analysis demonstrated that genes were associated with “amino acid metabolism,” “neutrophil degranulation,” and “DNA damage response”. We evaluated the prognostic impacts of the 43 genes in acute myeloid leukemia patients using TCGA database. The results revealed that two genes (<em>HDC</em> and <em>MICALL2</em>) with increased expression in leukemia cells after 5-Aza treatment were associated with better overall survival, while six genes (<em>BTG2</em>, <em>CD52</em>, <em>PECAM1</em>, <em>PIK3IP1</em>, <em>PTGS2</em>, and <em>TREML2</em>) correlated with worse overall survival. This study revealed that the epigenetic regulation by DNA demethylation in intron 1 has an important role of 5-Aza treatment in myeloid leukemia cells, and suggests novel targets for the development of combination therapy with 5-Aza.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"158 ","pages":"Article 108112"},"PeriodicalIF":2.2,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145156766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low-dose ropeginterferon alfa-2b and peginterferon alfa-2a have comparable efficacy and tolerability in polycythemia vera 低剂量聚乙二醇干扰素α α -2b和聚乙二醇干扰素α α -2a治疗真性红细胞增多症的疗效和耐受性相当

IF 2.2 4区医学

Leukemia research Pub Date : 2025-09-19 DOI: 10.1016/j.leukres.2025.108110

Neville Lee Jr, Katie Erdos, Aqib Abdul Rahman, Richard T. Silver, Joseph M. Scandura, Ghaith Abu-Zeinah

引用次数: 0

Health system costs and autologous stem cell transplant receipt for participants with multiple myeloma in the Australian 45 and Up Study 澳大利亚45岁及以上研究中多发性骨髓瘤参与者的医疗系统费用和自体干细胞移植收据。

IF 2.2 4区医学

Leukemia research Pub Date : 2025-09-16 DOI: 10.1016/j.leukres.2025.108100

Sarsha Yap , Anna Kelly , David Goldsbury , Marianne F. Weber , Xue Qin Yu , Qingwei Luo , Karen Canfell , Eleonora Feletto

{"title":"Health system costs and autologous stem cell transplant receipt for participants with multiple myeloma in the Australian 45 and Up Study","authors":"Sarsha Yap , Anna Kelly , David Goldsbury , Marianne F. Weber , Xue Qin Yu , Qingwei Luo , Karen Canfell , Eleonora Feletto","doi":"10.1016/j.leukres.2025.108100","DOIUrl":"10.1016/j.leukres.2025.108100","url":null,"abstract":"<div><h3>Background</h3><div>In Australia, the number of people living with multiple myeloma (MM) is projected to increase. We examined the health system costs and autologous stem cell transplant (ASCT) receipt among participants with MM diagnosed between 2006 and 2019 from the Australian 45 and Up Study cohort (267,357 participants).</div></div><div><h3>Materials and methods</h3><div>We identified 520 participants diagnosed with MM using cancer registry records. Direct excess health system costs were calculated by subtracting the mean values observed for 2533 matched participants without cancer from those observed for participants with MM. Costs were calculated from 2 years pre-diagnosis up to 5 years post-diagnosis, for different phases of care and at end of life. Participant characteristics associated with health system costs were analysed using gamma regression. Characteristics associated with ASCT receipt were analysed using competing risks regression.</div></div><div><h3>Results</h3><div>Mean excess health system cost per person was $8846 in the year pre-diagnosis and peaked at $66,249 in the year post-diagnosis. From 2- to 5-years post-diagnosis, mean excess costs per person ranged between $36,453 and $43,059 and remained substantially higher than pre-diagnosis levels. Within the 5-years post-diagnosis, 125 (24.0 %) received ASCT. Older age at diagnosis was strongly associated with lower costs (each one-year increase, relative rate (RR)= 0.97, 95 % CI:0.96–0.98 for initial phase of care costs) and a lower rate of ASCT (each one-year increase, sub-hazard ratio (SHR)= 0.85, 95 % CI:0.83–0.87).</div></div><div><h3>Conclusions</h3><div>Health system costs for individuals with MM were significantly higher post-diagnosis than pre-diagnosis and remained elevated for at least 5-years. This work provides insights for future healthcare requirements for MM.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"158 ","pages":"Article 108100"},"PeriodicalIF":2.2,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0